 Connection
Aravindhan Veerapandiyan to Genetic Therapy
This is a "connection" page, showing publications Aravindhan Veerapandiyan has written about Genetic Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.436 |
|
|
|
-
Veerapandiyan A, Duvuru R. Transforming care for spinal muscular atrophy: A critical look at treatment paradigms. Mol Ther. 2024 Aug 07; 32(8):2435-2436.
Score: 0.807
-
Muntoni F, Nascimento A, Shin J, Guglieri M, Stettner GM, Veerapandiyan A, Gallo S, Shi H, Gundapaneni B, Neelakantan S, Lobello K, Shen Q, Levy DI, Mercuri E. Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study. Lancet Neurol. 2026 Mar; 25(3):245-255.
Score: 0.226
-
Shieh PB, Proud C, Diamond T, Chapin CA, Ahmad J, Salama AD, B?nnemann CG, Soslow J, Byrne BJ, Veerapandiyan A, Brandsema JF, Matesanz S, Samelson-Jones BJ, Wilkins BJ, Gerber M, Godwin Wild KE, Mason S, Asher D, McDonald CM, Mendell JR. Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management. Hum Gene Ther. 2026 Mar; 37(5-6):262-279.
Score: 0.225
-
Wolff JM, Capocci N, Atas E, Bharucha-Goebel DX, Brandsema JF, Butterfield RJ, Chadwick CB, Corti M, Crawford TO, Cripe L, Day JW, Duong T, ElMallah MK, Flanigan KM, George LA, Goedeker NL, Goude E, Hesterlee S, Lin B, Katz NK, Matesanz SE, McDonald C, McNally EM, Mercado-Rodriguez C, Nandi D, Parsons JA, Proud C, Ramos-Platt L, Lek A, Salabarria SM, Camino E, Schrader R, Shea E, Shell R, Shieh PB, Soslow JH, Taylor JB, Veerapandiyan A, Villa C, Yang ML, Zaidman CM, Leon-Astudillo C, Byrne BJ. Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophy. Neuromuscul Disord. 2025 Sep; 54:106208.
Score: 0.218
-
Kaufman BD, Veerapandiyan A, Soslow JH, Wittlieb-Weber C, Esteso P, Olson AK, Shih R, Bansal N, Lal A, Gambetta K, Hsu D, Cripe L, Villa C, Nandi D. Taking ACTION to detect myocarditis related to recombinant gene transfer therapy for Duchenne Muscular Dystrophy; Consensus recommendations for cardiac surveillance. J Neuromuscul Dis. 2025 Mar; 12(2):173-182.
Score: 0.208
-
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025 Jan; 31(1):332-341.
Score: 0.205
-
Hamid OA, Hester DM, Matesanz SE, Wright S, Batley KY, Proud CM, Veerapandiyan A. Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion. Pediatr Neurol. 2024 Oct; 159:33-34.
Score: 0.202
-
Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, Godwin KE, Hor KN, Mathews KD, Proud CM, Kula Smyth E, Veerapandiyan A, Watkins PB, Mendell JR. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2024; 11(3):687-699.
Score: 0.194
-
Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, Mack CL. Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. J Pediatr. 2020 10; 225:252-258.e1.
Score: 0.151
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|